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microarraysgene expressiongenomicsgene expression profiling Introduction
The mechanisms underlying the basis of heredity and the
beginning of understanding of the genetic basis of life
began to be unravelled some 160 years ago. These funda-
mental concepts, which have paved the way for the cur-
rent explosion in our understanding of the genetic basis of
cellular function, were established from the study of pea
plants by an Augustinian monk, Gregor Mendel. The next
major development in genetics was 100 years later when
Watson and Crick discovered the structure of DNA. Fol-
lowing on from their seminal work there has been an
exponential growth in knowledge regarding the structure
and function of DNA and its functional unit, the gene [1].
The study of DNA itself is just a broad overview of the
human genome (genomics). When trying to understand
more complex genetic-based traits and diseases, such as
cancer, this is inadequate because it does not allow a thor-
ough understanding of the complex inter-related proc-
esses occurring within the cell. In order to take this
further, the functions of the individual genes, the messen-
ger RNA resulting from the gene and the subsequent pro-
tein, which is produced, need to be examined.
Furthermore, there are complex interactions between the
cellular environment and the genes, which can affect
genetic and cellular function.
The measurement of gene expression can, therefore, pro-
vide information on regulatory mechanisms, biochemical
pathways, cellular control mechanisms and potential tar-
gets for intervention and therapy in a variety of disease
states. One technique, which allows this to be studied, is
DNA microarray technology, which is now used to moni-
tor the expression of thousands of genes simultaneously.
This paper outlines briefly the applications, limitations
and the possible future of microarray techniques in onco-
logical research.
Gene expression
The gene sequences, which are contained in DNA, are
transcribed into messenger RNA (mRNA). These mRNAs
encode all the information required to synthesize proteins
that are the cellular effector molecules and are hence
coded for by DNA. Quantifying mRNA sequences presents
difficulties, not least of which is that there may be
extremely small amounts present within the cell. Further-
more, the mRNA molecule itself is very quickly degraded.
Robust and sensitive techniques have been developed to
allow an assessment of mRNA. The Reverse Transcription-
Polymerase Chain Reaction (RT-PCR) was, until recently,
the gold standard of mRNA expression analysis, which
allowed the de novo synthesis of mRNA to be assessed
using the DNA as the template on which mRNA could be
formed. Thus having formed mRNA, the technique of
real-time RT-PCR was then able to provide quantitative
data on mRNA synthesis.
RT-PCR has many limitations, one of which is that it relies
on specific primer sequences, termed probes. Further-
more, it is often only used to study one or several RNA
messages, at best, at one time. The novel development of
the DNA microarray technique in 1995 has altered the
concepts and assessments of mRNA expression [2]. This
method, which allows the analysis of thousands of genes,
simultaneously, in one single experiment is a
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phenomenal development in molecular biological
research methodology.
DNA microarray technology
A microarray consists of either complementary DNA
(cDNA) arranged in a particular order onto glass slides or
nylon membranes, and oligonucleotide arrays that com-
prise short DNA sequences (oligonucleotides) synthe-
sized directly onto the slide. This slide is also termed a
"chip".
The cDNA sequences, or oligonucleotides, correspond to
genes, which may be previously identified or unidentified
ones. RNA from biological samples, for example, blood,
normal tissues or tumour samples, is used to create com-
plementary cDNA. This is used to "probe" the arrays to
determine if a specific gene is present. However in micro-
array terminology, the "probe" is actually the physically
bound oligonucleotide or cDNA sequence [3].
The level of expression of each of the "probes" is deter-
mined by a specific detection method. Briefly, the bound
target sequences are labelled with a (usually fluorescent or
light producing) dye, or chemical, which can be detected
visually. Once the targets have bound to the probes on the
array, everything else is removed by washing. Scanning
equipment is then used to produce a digital image of the
signals produced, and these images are used for analysis.
Computer software packages are available which are used
to determine the levels of expression of a particular
mRNA, based on the strength of signal produced. This
data can then be compared with that from different chips
or samples. Statistical analysis is then used to determine
the significance of any changes in gene expression taking
place (Figure 1).
Applications of microarrays to oncological 
research
One of the initial applications of microarray analysis was
in tumour classification and identification of tumour
markers (oncogenomics). Microarray analysis initially
revealed two previously unknown and distinct types of
diffuse large B-cell lymphomas. One of these types had a
better prognosis than the others in terms of survival [4].
Subsequently, the use of oligonucleotide arrays in ovarian
cancers and tumour cell lines allowed a comparison with
cells from the normal tissue of origin to be made [5]. It
proved to be possible to identify groups of tumours on the
basis of their genetic profile. Moreover, tumours were
readily identifiable when compared with normal tissues.
A subset of candidate genetic markers for the malignant
process were identified for further study, for example, the
HE4 gene (a proposed ovarian tumour marker) and CD24
gene (codes for a protein involved in breast cancer cell
motility).
Microarray analysis has also been applied to the study of
drug sensitivity and also in the identification of novel
therapeutic agents (pharmacogenomics). Discovering, a
target for a drug, identifying a compound suitable for that
target and long-term clinical studies can all be furthered
by using microarray analysis. For example, in the case of
response to a known drug, cDNA microarrays were uti-
lized to monitor the expression profiles (a particular pat-
tern of genes being expressed) of breast cancer cell lines,
which were either sensitive or resistant to doxorubicin. In
this study, a distinct set of genes which were altered during
treatment with doxorubicin and another subset of genes,
were also identified, which were constitutively expressed
in cells that were resistant to doxorubicin treatment [6].
Therefore, this opens up the possibility of ex vivo testing
(before the commencement of any therapy) of a tumour
biopsy to allow the identification of the appropriate
chemotherapeutic agent for an individual patient.
The identification of interactions between therapeutic
agents and genes (drug-gene interactions) has also uti-
lized microarray technology. One such example was the
examination of the effectiveness of 118 possible agents,
which had anti-cancer activity, against 60 different cancer
cell lines [7]. In particular, 78% of cell lines with low
expression of the dihydropyrimidine dehydrogenase gene
(DPYD) were more sensitive to 5-fluorouracil (5-FU). As
Simplified protocol for microarray analysis Figure 1
Simplified protocol for microarray analysis. a) RNA or 
mRNA from sample of interest is converted into cDNA. b) 
cDNA is applied to the microarray slide. c) Target cDNA 
and probes are hybridised under specific conditions. d) The 
completed chip is scanned and converted into raw data. e) 
Data is analysed by computer software. Different samples are 
indicated in red and green.World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/21
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5-FU is commonly used for, and is one of the most
effective agents used in the treatment of colon cancer the
results of the study suggested that DPYD may have poten-
tial clinical use in patients with colon cancer.
Microarrays can also be used to elucidate complex bio-
chemical pathways that occur in vivo. For example, oligo-
nucleotide microarray technology was utilized to
determine changes in gene expression between pre-adi-
pocytes and adipocytes in vitro and in vivo [8]. A number
of previously uncharacterised gene regulatory elements in
the pathway in vitro were demonstrated. Furthermore,
there was also a difference in gene expression between the
in vitro and in vivo pathways. This may be of fundamental
importance in understanding adipogenesis, which had
previously only been understood at a more elementary
level previously.
Analysis of mutations and polymorphisms is still a crucial
part of understanding the mechanisms of disease, in par-
ticular malignant disease. Polymorphisms are actually just
differences in DNA sequence at a particular location but
occurring more frequently than can be attributed to their
arising because of a mutation alone. Polymorphisms may
have no effect on cellular function and may therefore be
of no clinical consequence. However, sometimes they
may be associated with disease and may be useful for trac-
ing the progression of a disease-causing gene through
families. Analysis of possible mutations may involve
either determining the presence of previously character-
ized mutations, or alternatively, searching for all possible
mutations in a sequence of DNA. One of the initial uses
of screening for mutations using microarrays was the
identification of all 37 known mutations in the cystic
fibrosis (CF) gene, and in addition, this allowed the doc-
umentation of all the possible nucleotide substitutions
[9].
Further studies have detailed the feasibility and accuracy
of large-scale identification, mapping and genotyping of
polymorphisms using microarray techniques [10]. Muta-
tion analysis of the p53 gene, the most frequently mutated
gene in human cancer, has also been improved by use of
microarrays [11]. This study demonstrated an increased
sensitivity and a more accurate detection of known muta-
tions using microarray mutation analysis.
Application of microarrays to the clinical setting
As already discussed, microarrays have been used already
to identify novel classes of B cell lymphomas [4]. Several
studies have shown that microarray analysis can allow the
identification of novel subtypes of breast tumours (two
new subgroups of luminal epithelial/oestrogen receptor
positive tumours), and predict subsequent clinical out-
come. This may allow, therefore, targeting of therapy such
as adjuvant chemotherapy to be given to those patients
who have the worst prognosis and are in most need of
such treatment [12–14].
Microarrays have also been used to classify and predict
prognosis for other cancers such as oesophageal, endome-
trial, and renal carcinoma. For example, the sensitivity of
oesophageal tumours to chemotherapy could be given a
response score based on the expression levels of a set of
genes identified by microarray analysis. When applied to
six unknown test samples, the response score correctly
placed all tumours into the correct response groups [15].
Hepatocellular carcinoma could be categorized as either
solid or pseudo-glandular types [16], and a revised classi-
fication of renal carcinoma was suggested by Higgins et al
[17]. In particular, they identified distinct molecular
expression profiles between usual renal cell carcinomas
with granular cytoplasm, when compared with those with
clear cytoplasm – which had been previously classed
together as "conventional" carcinomas. One recent study
has shown that microarrays could be used to identify par-
ticular expression profiles in patients with diffuse large B-
cell lymphoma, which could predict their long term sur-
vival with 100% accuracy [18].
An extremely important area where clinicians are faced
with diagnostic difficulties are with those patients who
present metastatic disease from an unknown primary site.
Palliative chemotherapy may prolong life but appropriate
therapy is dependant on identification of the tissue of ori-
gin of the tumour. Arrays may prove to be useful tools in
identifying the primary site of such metastases [19]. A
recent study revealed that microarray analysis of the met-
astatic tissue resulted in correct identification of the pri-
mary site of origin in 81% of patients studied.
Limitations of microarray technology
One major disadvantage that occurred in the early years of
microarray research was their financial cost. This resulted
in the restriction of their use to well-funded larger labora-
tories, with these costs being beyond the funding scope of
most academic research laboratories. In recent years, how-
ever, the costs of this technology has decreased as a result
of advances in manufacturing technology and commercial
competition to develop and make this technology availa-
ble to as large a market as possible. Indeed, many research
laboratories can manufacture their own arrays for rela-
tively little cost. Spotted cDNA arrays, and arrays pro-
duced "in house" also have problems of standardization
and consistency, with there being possible variations
between experiments. Rigorous quality control is required
to ensure that genetic changes, which are identified, are
not simply due to defects and variations between arrays.
Affymetrix™ oligonucleotide gene chips, however, have a
multitude of internal controls within the arrays to accountWorld Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/21
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for any variation between arrays (normalization) as well
as controls for correct hybridisation of targets.
One of the main drawbacks of DNA microarray technol-
ogy is that the levels of mRNA expression do not necessar-
ily represent the levels of proteins in the cell. It is well
recognized that proteins can also be altered by a variety of
processes, which occur following transcription of DNA to
mRNA or after translation of mRNA into its protein. This
fact means that any interesting changes suggested by an
array experiment must be further verified by RT-PCR or
northern blot analysis (to ensure the altered expression
does actually exist) and western analysis to determine
changes in the protein levels.
It has become generally accepted that when using array
analysis that a "real" change exists when there is an appar-
ent 2-fold, or higher, change in gene expression. This
means that smaller degrees of change, which may be just
as important, will more often than not remain unrecog-
nised, unless they were specifically looked for initially.
The complexity of microarray analysis means that tissue
sample collection becomes a crucial factor in the data pro-
duced. As microarrays have been used with increasing fre-
quency in recent years the amount of diversity in gene
expression between samples, even from the same tissue in
the same individual, has become clear. Precise sampling
(including factors such as the time of day and month
taken) and the ability to sample homogeneous tissue sam-
ples (by using techniques such as laser capture microdis-
section) [20], are crucial steps in obtaining an accurate
analysis. At the same time, the amount of tissue required
can also be a problem as a relatively large amount of RNA
is required. However, more recent techniques to amplify
RNA have been developed to allow extraction from
minute tissue samples [21,22].
Future application of microarrays – Individualized Therapy Figure 2
Future application of microarrays – Individualized Therapy. A. Currently, patients are likely to be given the treatment based on 
the best available drug at the time. B. Pre-treatment testing may allow the treatment to be tailored to a particular individual 
based on their gene expression profileWorld Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/21
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As arrays have become more and more complex, the data
analysis of the results produced has also become more
complicated such that it can take considerable time to
analyse using powerful computers to produce the
required data. Data acquisition and processing via a vari-
ety of statistical methods can identify unique patterns or
profiles of gene expression. Once a set of genes of interest
has been identified the ever-expanding public and com-
mercial databases then have to be interrogated (data min-
ing) to determine any proposed functional effects of these
changes in expression. Complicated statistical algorithms
and artificial intelligence networks are now used to
"trawl" through the vast amounts of data, which may be
produced from a single study [18,23].
The Future
As microarray technology becomes more advanced, arrays
will be able to offer an increased ability to unravel com-
plex disease processes and determine new targets for ther-
apeutic interventions. Affymetrix™ now has made
available a microarray chip, which contains the sequences
of over 11,000 polymorphic sites in the genome [24]. In
the past, researchers concentrated on one, or a small
group of single nucleotide polymorphisms (SNPs), at any
one time, because they were limited by the need to design
primer sets for each SNP. Now, one array can give the
information for one individual for thousands of SNPs, in
one experiment.
Further developments in nanotechnology have enabled
the production of the SmaSeq™, a single molecule array,
which should allow the complete sequencing of an entire
individual in one reaction and on one array chip [25]. The
sequence would then be compared to a reference
sequence and alterations recorded. This type of technol-
ogy opens up the door to the possibility of individualized
therapy where diagnosis and therapy of a disease will be
specifically tailored to the individual patient (Figure 2).
Conclusions
Microarrays have revolutionised genetic and medical
research over the last 10 years. Despite the initial limita-
tions of variability and cost, microarrays are now more
comprehensive and accurate and are easily available to
most research laboratories. It is now possible to analyse
thousands of genes at the same time in one experiment,
and differences, or similarities, between individuals can
be determined quickly and easily. As they are used more
and more in clinical applications, microarrays will be
adapted for diagnostic procedures and used to determine
specific treatment regimens, tailored for individual
patients.
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